Shanghai Jinli Bio-tech

Shanghai Jinli Bio-tech is a Chinese biotechnology company specializing in the development of next-generation gene editing technologies, including base editing and prime editing. Founded as a spin-off from ShanghaiTech University by leading scientists in the field, the company aims to create highly precise and efficient genetic medicines for the treatment of rare and intractable diseases. Their platform focuses on overcoming the limitations of traditional CRISPR-Cas9 systems, such as off-target effects and low efficiency in non-dividing cells. Jinli Bio is currently in the pre-clinical stage, advancing a pipeline of in vivo therapies targeting various genetic indications. The company has secured significant venture capital funding to support its R&D efforts and the translation of academic breakthroughs into clinical applications.